Similar articles

• Neuromuscular Effects of Rocuronium Bromide in Patients in Statin Therapy for at least Three Months.

  Ren H, Lv H. Ren H, et al. Basic Clin Pharmacol Toxicol. 2016 Dec;119(6):582-587. doi: 10.1111/bcpt.12628. Epub 2016 Jun 24. Basic Clin Pharmacol Toxicol. 2016. PMID: 27234897
• Changes in muscle strength in individuals with statin-induced myopathy: A summary of 3 investigations.

  Panza GA, Taylor BA, Dada MR, Thompson PD. Panza GA, et al. J Clin Lipidol. 2015 May-Jun;9(3):351-6. doi: 10.1016/j.jacl.2015.01.004. Epub 2015 Jan 28. J Clin Lipidol. 2015. PMID: 26073393 Clinical Trial.
• Increased creatine kinase with statin treatment may identify statin-associated muscle symptoms.

  Taylor BA, Panza G, Thompson PD. Taylor BA, et al. Int J Cardiol. 2016 Apr 15;209:12-3. doi: 10.1016/j.ijcard.2016.02.028. Epub 2016 Feb 3. Int J Cardiol. 2016. PMID: 26874453 Free PMC article. Clinical Trial. No abstract available.
• Risk identification and possible countermeasures for muscle adverse effects during statin therapy.

  Magni P, Macchi C, Morlotti B, Sirtori CR, Ruscica M. Magni P, et al. Eur J Intern Med. 2015 Mar;26(2):82-8. doi: 10.1016/j.ejim.2015.01.002. Epub 2015 Jan 29. Eur J Intern Med. 2015. PMID: 25640999 Review.
• Muscle-related side-effects of statins: from mechanisms to evidence-based solutions.

  Taylor BA, Thompson PD. Taylor BA, et al. Curr Opin Lipidol. 2015 Jun;26(3):221-7. doi: 10.1097/MOL.0000000000000174. Curr Opin Lipidol. 2015. PMID: 25943841 Review.